[Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D013974:Thyroxine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014280:Triglycerides / Q000037:antagonists & inhibitors* / Q000097:blood
D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; C010150:etiroxate; D002994:Clofibrate; D013974:Thyroxine
Vergleichende Untersuchungen über den cholesterin- und triglyceridsenkenden Effekt von alpha-Methylthyroxin (Skleronorm) und Clofibrat (Regelan) bei Hyperlipoproteinämien der Typen IIa/b und IV.